{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".28","upperLimit":".64","value":".45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive:\n\nCycle 1:\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8\n\nCycle 2 (Cycle 2 delivered 24-36 weeks after Cycle 1):\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8.\n\nPatients also receive:\n\n480 mcg filgrastim (G-CSF) subcutaneously (SC) daily when ANC is less than 1500.\n\n50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000.","id":"OG000","title":"Treatment : Dose Level 6"}],"paramType":"NUMBER","populationDescription":"Forty-five patients were registered to Dose Level 6 (39 patients registered to the Phase II portion and 6 patients registered to Dose Level 6 in the Phase I portion). Of the 45 patients, 33 patients received 2 sequential doses of Y2B8 and were evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"At 3 years","title":"Proportion of Patients Who Receive 2 Sequential Doses of Y2B8 Immunotherapy and Are Progression-free (Phase II)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}